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unchanged trends in care.
It is important to note that although the Centers for Medicare
& Medicaid Services mandates participation in the ICD Registry
for hospitals performing ICD and CRT-D implantations, data are
not available on those patients who might be eligible but have not
been referred for or received an ICD. Likewise, those patients who
were offered therapy, but declined, are not included. Also, data are
not available to identify cases in which CRT-D was planned but
may have been aborted because of technical limitations; regardless,
these data would not have been affected by patient race or
ethnicity.
The use of CRT-D seems to be improving in the overall
population and in racial and ethnic subgroups; however, disparities
in the use of CRT-D have remained over time. Future efforts to
improve the broad and systematic use of CRT-D in eligible
patients are needed to minimize differences in care and improve
the treatment of patients with advanced HF.
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CRT-D Implantation Rates in Eligible Patients Over TimeTable 1 CRT-D Implantation Rates in Eligible Patients Over Time
Year First Year Second Year
Overall 21,758 (80.35) 21,957 (81.27)
Race
White 17,833 (80.99) 17,858 (82.27)
Black 2,306 (77.54) 2,324 (77.06)
Hispanic 1,091 (76.51) 1,201 (76.21)
Other race 528 (80.24) 574 (79.72)
Values are n (%).
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Letters to the Editor
Atrioventricular Nodal
Ablation in Heart Failure:
The Picture Is Clear But Incomplete
I would like to offer 2 comments on the systematic review by
Ganesan et al. (1) and the accompanying editorial by Gasparini
and Galimberti (2). First, the review suggests that atrioventricular
nodal ablation (AVNA) in patients who have atrial fibrillation
(AF) and biventricular pacing may reduce all-cause mortality.
Calculations based on the studies summarized in Tables 1 and 2
(1) showed that all-cause mortality in patients who had undergone
AVNA was 19 of 189 (about 10%) and 65 of 261 (about 25%); that
is, the number needed to treat (NNT) was approximately 7 over a
variable median follow-up of 6 to 34 months. These results are
indeed striking, particularly compared with results of randomized
trials of biventricular pacing in sinus rhythm versus medical
therapy alone (245 of 1,472 [about 17%] vs. 231 of 1,129 [about
20%]; that is, a 3% absolute reduction in all-cause mortality (3).
Even at 3 years, the NNT to prevent 1 death was 9 based on the
data from the Cardiac Resynchronization–Heart Failure study (4).
Although it is possible that the benefit of increasing the percent
biventricular pacing in patients with AF from85% (the criterion for
VNA in the largest study included in the review) to close to 100%
ith AVNA may exceed that of patients in sinus rhythm, it is more
lausible that the benefit of AVNA reported in this review is an
Third Year Fourth Year p Value
22,119 (81.97) 21,858 (84.02) 0.001
17,989 (82.82) 17,701 (84.84) 0.001
2,367 (78.22) 2,354 (81.09) 0.001
1,140 (77.18) 1,134 (78.97) 0.044
623 (81.76) 669 (82.39) 0.091xaggeration of the “true” benefit. Nonrandomized studies, particu-
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with larger treatment effects (5). In this regard, it is notable that all 3
studies which reported on mortality as an outcome in this review were
retrospective in design, and 2 of the 3 were single-center studies.
Second, the true safety of AVNA in patients who have heart
failure and AF should be assessed over the longer term (not simply
procedural safety) because it results in irreversible pacemaker
dependency. Short-term follow-up may not capture the long-term
risks of an irreversible procedure. What are the long-term risks,
therefore, of pacemaker dependency? The maximum follow-up in
the studies included in the review by Ganesan et al. (1) was a
median of 34 months, which is less than the lifetime of a
pacemaker/defibrillator generator. With significant risks associated
with generator replacement/revisions (particularly in patients with
biventricular pacemakers/defibrillators) (6), the clinical implications of
rreversible pacemaker dependency cannot be easily dismissed. Fur-
hermore, in patients who are less likely to respond to biventricular
acing (e.g., relatively narrow QRS duration and extensive areas of
nfarction), does the potential benefit of AVNA still outweigh the
otential complications of irreversible pacemaker dependency?
Hence, the current picture of AVNA in heart failure is
ncomplete. The need for randomized studies is clear.
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Ursodeoxycholic Acid in Patients
With Chronic Heart Failure
We read with interest the excellent paper written by von Haehling
et al. (1). The authors assessed, in a double-blind, randomized,placebo-controlled, crossover trial, the effects of ursodeoxycholic
acid (UDCA) on endothelial function and inflammatory markers
in patients with chronic heart failure (HF). They concluded that
UDCA improved peak post-ischemic blood flow in the arm and
that there was a trend for improved peak post-ischemic blood flow
in the leg, while liver function was improved. However, it failed to
show benefits in exercise capacity and levels of inflammatory
markers, such as tumor necrosis factor  and interleukin-6,
compared with placebo.
Previously, it was shown that 6 weeks’ UDCA therapy improved
endothelium-dependent, nitric oxide–independent vasodilatation,
which might maintain arterial flow in patients with HF under
conditions of impaired nitric oxide production (2). The present
study expanded the previous knowledge in patients with HF.
Despite the novelty of the present study, and although it was
published many years after the first study of UDCA, there are still
aspects requiring attention, such as the drug dose and the study
period. Furthermore, the implicated underlying pathways are
rather controversial and slightly inexplicable when considering the
unequal improvements of peripheral blood flow in the arms and
legs.
Similarly, we have highlighted previously the beneficial
effects of pharmaceutical agents, different from UDCA, on
endothelial function/inflammatory process in patients with HF,
and we have shown that short-term treatment with rosuvastatin
regulated the inflammatory process in patients with HF by
significantly reducing plasma levels of myeloperoxidase com-
pared with allopurinol and placebo (3). Importantly, treatment
with rosuvastatin, but not allopurinol, significantly increased
the number of circulating endothelial progenitor cells (EPCs) in
patients with HF, providing further insight into its role in these
individuals. This effect on EPCs was not mediated by changes
in inflammatory and oxidative status (4). Considering the
previously published data, we conclude that although the results
of the study by von Haehling et al. (1)are promising and
challenging, these should be considered with care and skepticism.
Agents such as statins and others already evaluated in several
studies are capable of improving endothelial function and decreas-
ing inflammatory process, and therefore further large-scale ran-
domized studies are required to establish the role of UDCA
therapy in patients with HF.
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